Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects
Sponsor
Daewoong Pharmaceutical Co. LTD. (Industry)
Overall Status
Completed
CT.gov ID
NCT02704559
Collaborator
(none)
40
1
2
2
19.6
Study Details
Study Description
Brief Summary
A randomized, open-label, oral dose, crossover study to explore drug-drug interactions between DWC20155 and DWC20156 in healthy subjects.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
40 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date
:
Dec 1, 2015
Actual Primary Completion Date
:
Feb 1, 2016
Actual Study Completion Date
:
Feb 1, 2016
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Study effect of DWC20156 on DWC20155 PK To study effect of DWC20156 on DWC20155 PK |
Drug: DWC20156
|
Experimental: Study effect of DWC20155 on DWC20156 PK To study effect of DWC20155 on DWC20156 PK |
Drug: DWC20155
|
Outcome Measures
Primary Outcome Measures
- Peak Plasma Concentration (Cmax) [0~24hr]
- Area under the plasma concentration versus time curve (AUC) [0~24h]
Eligibility Criteria
Criteria
Ages Eligible for Study:
19 Years
to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- Accepts healthy volunteers.
Exclusion Criteria:
- Who has allergy to investigational product
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Busan Paik Hospital | Busan | Korea, Republic of |
Sponsors and Collaborators
- Daewoong Pharmaceutical Co. LTD.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Daewoong Pharmaceutical Co. LTD.
ClinicalTrials.gov Identifier:
NCT02704559
Other Study ID Numbers:
- DW_DWJ1366001
First Posted:
Mar 10, 2016
Last Update Posted:
Feb 16, 2017
Last Verified:
Feb 1, 2017